Friday July 20, 2018
Home India Central gover...

Central government hospitals in India to reserve beds for Dengue, Chikungunya

At least 14 people have died in the national capital since the outbreak of the vector-borne disease in last a few days

3
//
170
Mosquito. Wikimedia
Republish
Reprint

NEW DELHI, Sept 16, 2016: The central government has agreed to reserve 10 percent of the beds in its hospitals for treatment of dengue and chikungunya patients, according to Delhi Health Minister Satyendar Jain.

Jain’s remarks came after meeting Union Health Minister J.P. Nadda at his office here on Friday.

“We had requested Mr Nadda to reserve at least 10 percent beds (1,000 beds) in the central government-run hospitals, like All India Institute of Medical Sciences (AIIMS), Safdarjung Hospital, Ram Manohar Lohia Hospital, etc., for treatment of dengue and chikungunya cases, to which he (Nadda) agreed,” Jain told reporters after the meeting.

Earlier, Jain had sought an appointment with Nadda and also written him a letter requesting the Union Minister to convene a meeting of the health ministers of neighbouring states.

Follow NewsGram on Facebook

AIIMS. Wikimedia
AIIMS. Wikimedia

He urged Nadda to ask health ministers of neighbouring states like Uttar Pradesh and Haryana to set up fever clinics in order to reduce excessive patient inflow in the hospitals of Delhi.

“The government should also advertise about these fever clinics, so that people could know about it,” he added.

Asked whether Delhi will take patients from other states, Jain said, “We are not denying treatment to anybody coming to Delhi For treatment.”

Follow NewsGram on Twitter

He also said that in Delhi government hospitals more than 1,500 beds are available, and there is no need for panic. “We are working day and night,” he added.

At least 14 people have died in the national capital since the outbreak of the vector-borne disease in last a few days. (IANS)

Click here for reuse options!
Copyright 2016 NewsGram

  • Manthra koliyer

    Dengue is really very dangerous

  • Arya Sharan

    Dengue and Chikungunya are life threatening diseases hence proper and efficient measures are required to be taken by the Government.

  • Antara

    Patients suffering from vector-borne diseases should be treated with more focus now!

Next Story

Dengue Vaccine Should Not Be Used Widely: UN Health Agency

UN Health Agency issued an important statement regarding the dengue vaccine

0
Dengue vaccine.
A Manila Health officer shows off a pair of vials of the anti-dengue vaccine Dengvaxia after being recalled from local government health centers Tuesday, Dec. 5, 2017 in Manila, Philippines. The World Health Organization says the first-ever vaccine for dengue needs to be dealt with in "a much safer way," meaning that the shot should mostly be given to people who have previously been infected with the disease. VOA

The World Health Organization says the first-ever vaccine for dengue needs to be dealt with in “a much safer way,” meaning that the shot should mostly be given to people who have previously been infected with the disease.

In November, the vaccine’s manufacturer, Sanofi Pasteur, said people who had never been sickened by dengue before were at risk of developing a more serious disease after getting the shot.

After a two-day meeting this week, WHO’s independent vaccines group said it now had proof the vaccine should only be used “exclusively or almost exclusively in people who have already been infected with dengue.”

Also Read: Anti-dengue Antibody Drug May Neutralize Zika Virus

The U.N. health agency said a test should be developed so doctors would be able to quickly tell if people had previously been sickened by dengue – but the group acknowledged doing that so isn’t straightforward.

“We see significant obstacles in using the vaccine this way, but we are confident this also spurs the development of a rapid diagnostic test,” said Dr. Joachim Hombach, executive secretary of WHO’s expert group, during a news conference Thursday.

Representational image for dengue vaccination
Representational image. Wikimedia Commons

Sanofi said last year that doctors should consider whether people might have been previously infected with dengue before deciding whether they should risk getting immunized. The company said it expected to take a 100 million euro ($118 million) loss based on that news.

People who catch dengue more than once can be at risk of a hemorrhagic version of the disease. The mosquito-spread virus is found in tropical and sub-tropical climates across Latin and South America, Asia, Africa and elsewhere. It causes a flu-like disease that can cause joint pain, nausea, vomiting and a rash. In severe cases, dengue can result in breathing problems, hemorrhaging and organ failure.

About half the world’s population is at risk of dengue; WHO estimates that about 96 million people are sickened by the viral infection every year.

Also Read: Dengue fever may increase risk of stroke: Study

Following Sanofi’s announcement last year, the Philippines halted its dengue immunization program, the world’s first national vaccination program for dengue. The government also demanded a refund of more than 3 billion pesos ($59 million) from Sanofi and is considering further legal action.

In February, the Philippines said the vaccine was potentially linked to the deaths of three people: all of them died of dengue despite having received the vaccine.

The country imposed a symbolic fine of $2,000 on Sanofi and suspended the vaccine’s approval, charging that the drugmaker broke rules on how the shot was registered and marketed.

More than 730,000 children aged 9 and above in the Philippines have received at least one dose of the dengue vaccine, usually delivered in three doses.

There is no specific treatment for dengue and there are no other licensed vaccines on the market.  VOA